Semaglutide bests canagliflozin for HbA1c, weight reductions in T2D
19 Oct 2019
byRoshini Claire Anthony
In patients with type 2 diabetes (T2D) inadequately controlled on metformin, semaglutide may have a greater impact than canagliflozin in reducing HbA1c levels and bodyweight, according to the phase IIIb SUSTAIN 8* trial presented at EASD 2019.
Semaglutide bests canagliflozin for HbA1c, weight reductions in T2D
19 Oct 2019